Merck loses out on Cosopt patent; Sanofi wraps up Genzyme purchase;

@FiercePharma: GSK readies 500 reps for Horizant launch. Story | Follow @FiercePharma

> Merck has lost a U.K. court bid to reinstate its European patent for the glaucoma treatment Cosopt after a successful challenge by Teva Pharmaceutical Industries. Report

> Cephalon won a court order that prevents generic-drug makers from selling low-cost versions of its muscle relaxant Amrix until a judge rules on a patent dispute over the drug. News

> Sanofi-Aventis completed its takeover of U.S. biotech Genzyme, whose shares ceased trading on the Nasdaq as of the market close on Friday. Article

> Danish biopharma Bavarian Nordic said it had extended a smallpox contract with the U.S. government to $94 million from $40 million. Story

> Valeant Pharmaceuticals said it might be willing to increase its takeover offer for Cephalon if the U.S. drugmaker agreed to open its books to due diligence. Report

> Impax Laboratories said it will sell two softgel capsule drugs made by Banner Pharmacaps as part of a new partnership. Item

> Swiss drugs industry supplier Lonza is not interested in buying rivals Siegfried and Bachem, Lonza's chief executive told a Swiss newspaper. Story

> The United Arab Emirates' national fund for the purchase of medicines has doubled, from 150 million dirhams in 2010 to 300 million dirhams ($81 million) for this year. News

> GW Pharmaceuticals has signed up Novartis to sell its cannabis-based drug Sativex in a range of markets--including Australia, the Middle East and Africa--marking a key endorsement for the treatment from the major Swiss pharmaceutical company. Report  

> California's treasurer became the second state official to ask leading makers of AIDS medications to extend lower prices and rebates for drugs to help the state's budget crisis. News   

A British man was jailed for eight years for his role in supplying more than 2 million doses of fake medicines in the most serious known case of counterfeit drugs getting into the European supply chain. Story 

Biotech News

 @FierceBiotech: Beleaguered Ambrilia faces bankruptcy. Report | Follow @FierceBiotech  

 @JohnCFierce: CF Foundation clearly very impressed with Vertex. Doubles down on R&D pact, adds $75M. Story  | Follow @JohnCFierce

>  Biogen flags Ph3 success for crucial MS drug. Report

> Medivation's Dimebon flunks Ph3 for Huntington's disease. Article

> Third Rock launches cancer drug developer with $40M bankroll. Item

Biotech IT News

> LifeMap born to create stem cell database. Item 

> DZS Software enters partnership with Medidata. Story 

> PatientsLikeMe reveals strategy change. Article 

> Informatics enables new "point-of-care" trials. Report 

> Complete Genomics stocks up public genome repository. Item 

Medical Device News

> Depuy pays $7.9 million to end UK bribe case. Story 

> Medtronic combines U.S. cardiac, vascular sales groups. Report 

> PixelOptics snags $45M investment. Item 

> Biotronik responds to NYT report. Article 

> Study: Patients in stroke device trials don't resemble typical patients. Report 

> Endo to buy AMS for $2.9M. News 

> St. Jude signs contract with GPO Novation. Item 

And Finally... As prescription drug abuse ravages communities across the country, doctors are confronting an emerging challenge: newborns dependent on painkillers. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.